On Thursday, Beijing joined the World Health organization's Covax initiative-an global effort to develop and distribute vaccines for COVID-19 so that developing economies aren't left behind. "China will also strengthen vaccine cooperation with relevant countries through the COVAX network", said the spokesperson.
"That China joined the multilateral Covax framework "[shows] its ambition to be seen tackling COVID-19 instead of the United States", Kato says.
Initially, China did not agree to join the alliance, after missing an early deadline to join in September.
The decision comes after the US said last month that it would not join Covax, citing its ties to organizations close to China and the WHO, which the Trump administration has accused of being excessively influenced by Beijing.
China joining the network will be huge boost to the initiative as the U.S. had earlier said it would not participate in the scheme. As part of a Team Europe effort, the Commission announced is contributing with €400 million in guarantees to support COVAX and its objectives in the context of the Coronavirus Global Response.
Lead author of the study, S.S. Vasan from the CSIRO's Dangerous Pathogens Team, said the findings were good news for hundreds of vaccines being developed around the world.
House Antitrust Committee Says Apple Has iOS Distribution "Monopoly"
In its defence, Facebook said its acquisition of rival platforms Instagram and WhatsApp improved the apps for consumers. On top of that, the report describes "dozens of instances where companies misused their power".
In its new posting, the FDA said that vaccine makers must follow trial participants for at least two months to rule out safety issues. "I'm glad that we have been able to find an agreement with Johnson & Johnson to purchase vaccines for 200 million people", European Commission chief, Ursula von der Leyen said in a statement.
In this week's budget, the federal government committed to $1.7 billion in funding over two years towards the University of Oxford/AstraZeneca and University of Queensland/CSL Limited vaccines.
Covax is led by the Coalition for Epidemic Preparedness Innovations and the vaccine alliance Gavi.
In a separate development, Rentschler Biopharma agreed to serve as a contract development and manufacturing organisation (CDMO) partner for BioNTech, with focus on Covid-19 vaccine manufacturing support.
To date, China has not yet published any late-stage information about any of its vaccine candidates, despite starting to use some more broadly in targeted populations.
It is worth mention here that China has at least four experimental vaccines in the final works of clinical trials. "Our aim is to provide European Union citizens with safe and effective vaccines as soon as they are found". Once the authorities give the nod, the second Russian vaccine would be put to Phase 3 of clinical trials.